Transient Elastography (FibroScan(®)) with Controlled Attenuation Parameter in the Assessment of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease - Where Do We Stand?

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2016 Sep 14

PMID 27621571

Citations 121

Authors

Ivana Mikolasevic

Lidija Orlic

Neven Franjic

Goran Hauser

Davor Stimac

Sandra Milic

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Currently, the routinely used modalities are unable to adequately determine the levels of steatosis and fibrosis (laboratory tests and ultrasonography) or cannot be applied as a screening procedure (liver biopsy). Among the non-invasive tests, transient elastography (FibroScan(®), TE) with controlled attenuation parameter (CAP) has demonstrated good accuracy in quantifying the levels of liver steatosis and fibrosis in patients with NAFLD, the factors associated with the diagnosis and NAFLD progression. The method is fast, reliable and reproducible, with good intra- and interobserver levels of agreement, thus allowing for population-wide screening and disease follow-up. The initial inability of the procedure to accurately determine fibrosis and steatosis in obese patients has been addressed with the development of the obese-specific XL probe. TE with CAP is a viable alternative to ultrasonography, both as an initial assessment and during follow-up of patients with NAFLD. Its ability to exclude patients with advanced fibrosis may be used to identify low-risk NAFLD patients in whom liver biopsy is not needed, therefore reducing the risk of complications and the financial costs.

Citing Articles

There is a linear negative correlation between lipoprotein(a) and non-alcoholic fatty liver disease.

Li C, Li M, Wang Z Sci Rep. 2025; 15(1):8538.

PMID: 40074828 PMC: 11903960. DOI: 10.1038/s41598-025-93518-z.

Proof of concept pilot study to assess the utility of magnetic resonance extra-cellular volume quantification to diagnose advanced liver disease in people with Cystic Fibrosis.

Tewkesbury D, Scott J, Bright-Thomas R, Liong S, Naish J, Rudralingam V PLoS One. 2025; 20(3):e0318085.

PMID: 40036270 PMC: 11878935. DOI: 10.1371/journal.pone.0318085.

The feasibility of using liver function indices and FibroScan in combination to predict the occurrence of anti-tuberculosis drug-induced liver injury in Patients with liver disease.

Shaoqiang W, Qiaohua Y, Huai L, Yongzhong L J Med Biochem. 2025; 44(1):17-23.

PMID: 39991175 PMC: 11846638. DOI: 10.5937/jomb0-50878.

Association between TyG related parameters and metabolic dysfunction associated fatty liver disease among nondiabetic individuals.

Zhang Q, Liu Z, Zhang J, Yang S, Liu L Sci Rep. 2025; 15(1):4566.

PMID: 39915562 PMC: 11802835. DOI: 10.1038/s41598-024-84917-9.

FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease....

Dallio M, Romeo M, Di Nardo F, Vaia P, Napolitano C, Ventriglia L Int J Mol Sci. 2025; 26(2).

PMID: 39859475 PMC: 11765617. DOI: 10.3390/ijms26020761.

References

Li Y, Huang Y, Wang Z, Yang Z, Sun F, Zhan S . Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2015; 43(4):458-69. DOI: 10.1111/apt.13488. View

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R . Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37(4):917-23. DOI: 10.1053/jhep.2003.50161. View

Mueller S, Millonig G, Sarovska L, Friedrich S, Reimann F, Pritsch M . Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol. 2010; 16(8):966-72. PMC: 2828601. DOI: 10.3748/wjg.v16.i8.966. View

Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M . Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005; 128(2):343-50. DOI: 10.1053/j.gastro.2004.11.018. View

Ryoo J, Suh Y, Shin H, Cho Y, Choi J, Park S . Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol. 2014; 29(11):1926-31. DOI: 10.1111/jgh.12643. View

Wang Y, Fan Q, Wang T, Wen J, Wang H, Zhang T . Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis. Int J Clin Exp Med. 2016; 8(10):17654-63. PMC: 4694255. View

DAmbrosio R, Aghemo A, Fraquelli M, Rumi M, Donato M, Paradis V . The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol. 2013; 59(2):251-6. DOI: 10.1016/j.jhep.2013.03.013. View

Afdhal N . Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (N Y). 2013; 8(9):605-7. PMC: 3594956. View

Gennisson J, Deffieux T, Fink M, Tanter M . Ultrasound elastography: principles and techniques. Diagn Interv Imaging. 2013; 94(5):487-95. DOI: 10.1016/j.diii.2013.01.022. View

10.

Younossi Z, Otgonsuren M, Venkatesan C, Mishra A . In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism. 2012; 62(3):352-60. DOI: 10.1016/j.metabol.2012.08.005. View

11.

Pathik P, Ravindra S, Ajay C, Prasad B, Jatin P, Prabha S . Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India. Ann Gastroenterol. 2015; 28(2):281-286. PMC: 4367221. View

12.

Sandrin L, Fourquet B, Hasquenoph J, Yon S, Fournier C, Mal F . Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003; 29(12):1705-13. DOI: 10.1016/j.ultrasmedbio.2003.07.001. View

13.

Ganne-Carrie N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L . Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology. 2006; 44(6):1511-7. DOI: 10.1002/hep.21420. View

14.

Musso G, Gambino R, Cassader M, Pagano G . Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2010; 43(8):617-49. DOI: 10.3109/07853890.2010.518623. View

15.

Zhang T, Zhang Y, Zhang C, Tang F, Li H, Zhang Q . Prediction of metabolic syndrome by non-alcoholic fatty liver disease in northern urban Han Chinese population: a prospective cohort study. PLoS One. 2014; 9(5):e96651. PMC: 4011868. DOI: 10.1371/journal.pone.0096651. View

16.

Millonig G, Friedrich S, Adolf S, Fonouni H, Golriz M, Mehrabi A . Liver stiffness is directly influenced by central venous pressure. J Hepatol. 2009; 52(2):206-10. DOI: 10.1016/j.jhep.2009.11.018. View

17.

Kantartzis K, Peter A, Machicao F, Machann J, Wagner S, Konigsrainer I . Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes. 2009; 58(11):2616-23. PMC: 2768178. DOI: 10.2337/db09-0279. View

18.

Chan H, Wong G, Choi P, Chan A, Chim A, Yiu K . Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 2008; 16(1):36-44. DOI: 10.1111/j.1365-2893.2008.01037.x. View

19.

Wang J, Changchien C, Hung C, Eng H, Tung W, Kee K . FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. J Gastroenterol. 2009; 44(5):439-46. DOI: 10.1007/s00535-009-0017-y. View

20.

Bang K, Cho Y . Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med. 2015; 5(1):7-13. PMC: 4608226. DOI: 10.15280/jlm.2015.5.1.7. View